Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer.
暂无分享，去创建一个
L. Baker | R. Talley | R. Fraile | R. Brownlee | M. Samson | A. Samhouri | R. J. Fraile
[1] R. Gralla,et al. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma. , 1979, Cancer treatment reports.
[2] P. Woolley,et al. Phase I studies on chlorozotocin , 1978, Clinical pharmacology and therapeutics.
[3] P. Woolley,et al. Pharmacology of chlorozotocin Nsc-178248), a new nitrosourea antitumor agent. , 1976, Cancer treatment reports.
[4] T. Anderson,et al. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. , 1975, Cancer research.
[5] R. Gralla,et al. Phase I trial of chlorozotocin. , 1979, Cancer treatment reports.
[6] R. Fleischman,et al. Toxicology studies in mice, beagle dogs and rhesus monkeys given chlorozotocin (NSC 178, 248). , 1979, Toxicology.
[7] J. Montgomery,et al. Synthesis of chlorozotocin, the 2-chloroethyl analog of the anticancer antibiotic streptozotocin. , 1975, Journal of medicinal chemistry.